nodes	percent_of_prediction	percent_of_DWPC	metapath
Eletriptan—CYP2C19—Rosuvastatin—atherosclerosis	0.0423	0.0701	CbGbCtD
Eletriptan—CYP2C19—Simvastatin—atherosclerosis	0.0393	0.0652	CbGbCtD
Eletriptan—CYP2C19—Lovastatin—atherosclerosis	0.0385	0.0638	CbGbCtD
Eletriptan—CYP2D6—Niacin—atherosclerosis	0.0378	0.0627	CbGbCtD
Eletriptan—CYP2C9—Rosuvastatin—atherosclerosis	0.0352	0.0583	CbGbCtD
Eletriptan—ABCB1—Ezetimibe—atherosclerosis	0.0341	0.0566	CbGbCtD
Eletriptan—CYP2C9—Simvastatin—atherosclerosis	0.0327	0.0542	CbGbCtD
Eletriptan—CYP2C9—Pravastatin—atherosclerosis	0.032	0.053	CbGbCtD
Eletriptan—CYP2C9—Lovastatin—atherosclerosis	0.032	0.053	CbGbCtD
Eletriptan—ABCB1—Simvastatin—atherosclerosis	0.0317	0.0526	CbGbCtD
Eletriptan—ABCB1—Pravastatin—atherosclerosis	0.0311	0.0515	CbGbCtD
Eletriptan—ABCB1—Lovastatin—atherosclerosis	0.0311	0.0515	CbGbCtD
Eletriptan—CYP2D6—Simvastatin—atherosclerosis	0.0299	0.0496	CbGbCtD
Eletriptan—CYP2D6—Pravastatin—atherosclerosis	0.0293	0.0485	CbGbCtD
Eletriptan—CYP2D6—Lovastatin—atherosclerosis	0.0293	0.0485	CbGbCtD
Eletriptan—CYP3A4—Ezetimibe—atherosclerosis	0.0205	0.0339	CbGbCtD
Eletriptan—CYP3A4—Rosuvastatin—atherosclerosis	0.0205	0.0339	CbGbCtD
Eletriptan—CYP3A4—Simvastatin—atherosclerosis	0.019	0.0315	CbGbCtD
Eletriptan—CYP3A4—Pravastatin—atherosclerosis	0.0186	0.0308	CbGbCtD
Eletriptan—CYP3A4—Lovastatin—atherosclerosis	0.0186	0.0308	CbGbCtD
Eletriptan—HTR7—vein—atherosclerosis	0.00434	0.136	CbGeAlD
Eletriptan—HTR1B—artery—atherosclerosis	0.00229	0.0721	CbGeAlD
Eletriptan—HTR1D—artery—atherosclerosis	0.00222	0.0698	CbGeAlD
Eletriptan—Clemastine—HRH1—atherosclerosis	0.00214	0.559	CrCbGaD
Eletriptan—HTR1B—blood vessel—atherosclerosis	0.00178	0.0562	CbGeAlD
Eletriptan—HTR7—artery—atherosclerosis	0.00177	0.0556	CbGeAlD
Eletriptan—HTR1D—blood vessel—atherosclerosis	0.00173	0.0544	CbGeAlD
Eletriptan—HTR7—endothelium—atherosclerosis	0.00149	0.047	CbGeAlD
Eletriptan—HTR7—blood vessel—atherosclerosis	0.00138	0.0433	CbGeAlD
Eletriptan—PTGS1—artery—atherosclerosis	0.00122	0.0384	CbGeAlD
Eletriptan—PTGS1—endothelium—atherosclerosis	0.00103	0.0325	CbGeAlD
Eletriptan—Mesoridazine—HRH1—atherosclerosis	0.000963	0.251	CrCbGaD
Eletriptan—PTGS1—blood vessel—atherosclerosis	0.000951	0.0299	CbGeAlD
Eletriptan—HTR1D—connective tissue—atherosclerosis	0.000886	0.0279	CbGeAlD
Eletriptan—CYP2A6—adipose tissue—atherosclerosis	0.000822	0.0259	CbGeAlD
Eletriptan—HTR1B—cardiovascular system—atherosclerosis	0.000796	0.0251	CbGeAlD
Eletriptan—HTR1D—cardiovascular system—atherosclerosis	0.000771	0.0243	CbGeAlD
Eletriptan—Thioridazine—HRH1—atherosclerosis	0.000726	0.19	CrCbGaD
Eletriptan—HTR2B—cardiovascular system—atherosclerosis	0.000717	0.0226	CbGeAlD
Eletriptan—HTR7—connective tissue—atherosclerosis	0.000705	0.0222	CbGeAlD
Eletriptan—HTR1A—cardiovascular system—atherosclerosis	0.000642	0.0202	CbGeAlD
Eletriptan—HTR2B—adipose tissue—atherosclerosis	0.000632	0.0199	CbGeAlD
Eletriptan—HTR7—cardiovascular system—atherosclerosis	0.000614	0.0193	CbGeAlD
Eletriptan—CYP2A6—liver—atherosclerosis	0.000576	0.0181	CbGeAlD
Eletriptan—ABCB1—blood vessel—atherosclerosis	0.000562	0.0177	CbGeAlD
Eletriptan—PTGS1—connective tissue—atherosclerosis	0.000488	0.0153	CbGeAlD
Eletriptan—CYP2C9—cardiovascular system—atherosclerosis	0.000465	0.0146	CbGeAlD
Eletriptan—Hypoaesthesia—Pravastatin—atherosclerosis	0.000463	0.002	CcSEcCtD
Eletriptan—Flatulence—Ezetimibe—atherosclerosis	0.000463	0.002	CcSEcCtD
Eletriptan—Pharyngitis—Pravastatin—atherosclerosis	0.000461	0.00199	CcSEcCtD
Eletriptan—Chills—Simvastatin—atherosclerosis	0.000461	0.00199	CcSEcCtD
Eletriptan—Muscle spasms—Lovastatin—atherosclerosis	0.00046	0.00198	CcSEcCtD
Eletriptan—Visual impairment—Niacin—atherosclerosis	0.000455	0.00196	CcSEcCtD
Eletriptan—Alopecia—Simvastatin—atherosclerosis	0.000454	0.00196	CcSEcCtD
Eletriptan—Back pain—Ezetimibe—atherosclerosis	0.000454	0.00196	CcSEcCtD
Eletriptan—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000452	0.00195	CcSEcCtD
Eletriptan—Muscle spasms—Ezetimibe—atherosclerosis	0.000451	0.00195	CcSEcCtD
Eletriptan—Tremor—Lovastatin—atherosclerosis	0.000448	0.00193	CcSEcCtD
Eletriptan—Visual impairment—Pravastatin—atherosclerosis	0.000448	0.00193	CcSEcCtD
Eletriptan—Ill-defined disorder—Lovastatin—atherosclerosis	0.000444	0.00192	CcSEcCtD
Eletriptan—Flatulence—Simvastatin—atherosclerosis	0.000441	0.0019	CcSEcCtD
Eletriptan—Tinnitus—Niacin—atherosclerosis	0.00044	0.0019	CcSEcCtD
Eletriptan—Dysgeusia—Simvastatin—atherosclerosis	0.000438	0.00189	CcSEcCtD
Eletriptan—Flushing—Niacin—atherosclerosis	0.000438	0.00189	CcSEcCtD
Eletriptan—Angioedema—Lovastatin—atherosclerosis	0.000437	0.00189	CcSEcCtD
Eletriptan—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000436	0.00188	CcSEcCtD
Eletriptan—Anaemia—Ezetimibe—atherosclerosis	0.000434	0.00187	CcSEcCtD
Eletriptan—Tinnitus—Pravastatin—atherosclerosis	0.000434	0.00187	CcSEcCtD
Eletriptan—Malaise—Lovastatin—atherosclerosis	0.000432	0.00186	CcSEcCtD
Eletriptan—Flushing—Pravastatin—atherosclerosis	0.000432	0.00186	CcSEcCtD
Eletriptan—Muscle spasms—Simvastatin—atherosclerosis	0.00043	0.00186	CcSEcCtD
Eletriptan—Vertigo—Lovastatin—atherosclerosis	0.00043	0.00185	CcSEcCtD
Eletriptan—Angioedema—Ezetimibe—atherosclerosis	0.000429	0.00185	CcSEcCtD
Eletriptan—Leukopenia—Lovastatin—atherosclerosis	0.000428	0.00185	CcSEcCtD
Eletriptan—PTGS1—cardiovascular system—atherosclerosis	0.000424	0.0134	CbGeAlD
Eletriptan—Chills—Niacin—atherosclerosis	0.000424	0.00183	CcSEcCtD
Eletriptan—Malaise—Ezetimibe—atherosclerosis	0.000423	0.00183	CcSEcCtD
Eletriptan—Arrhythmia—Niacin—atherosclerosis	0.000422	0.00182	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00042	0.00181	CcSEcCtD
Eletriptan—Tremor—Simvastatin—atherosclerosis	0.000419	0.00181	CcSEcCtD
Eletriptan—Alopecia—Niacin—atherosclerosis	0.000417	0.0018	CcSEcCtD
Eletriptan—Chills—Pravastatin—atherosclerosis	0.000417	0.0018	CcSEcCtD
Eletriptan—Insomnia—Rosuvastatin—atherosclerosis	0.000417	0.0018	CcSEcCtD
Eletriptan—Ill-defined disorder—Simvastatin—atherosclerosis	0.000415	0.00179	CcSEcCtD
Eletriptan—Arrhythmia—Pravastatin—atherosclerosis	0.000415	0.00179	CcSEcCtD
Eletriptan—Palpitations—Ezetimibe—atherosclerosis	0.000415	0.00179	CcSEcCtD
Eletriptan—Paraesthesia—Rosuvastatin—atherosclerosis	0.000414	0.00179	CcSEcCtD
Eletriptan—Anaemia—Simvastatin—atherosclerosis	0.000414	0.00178	CcSEcCtD
Eletriptan—Alopecia—Pravastatin—atherosclerosis	0.000411	0.00177	CcSEcCtD
Eletriptan—Cough—Ezetimibe—atherosclerosis	0.00041	0.00177	CcSEcCtD
Eletriptan—Angioedema—Simvastatin—atherosclerosis	0.000409	0.00176	CcSEcCtD
Eletriptan—Arthralgia—Lovastatin—atherosclerosis	0.000407	0.00176	CcSEcCtD
Eletriptan—Myalgia—Lovastatin—atherosclerosis	0.000407	0.00176	CcSEcCtD
Eletriptan—Anxiety—Lovastatin—atherosclerosis	0.000406	0.00175	CcSEcCtD
Eletriptan—Dyspepsia—Rosuvastatin—atherosclerosis	0.000406	0.00175	CcSEcCtD
Eletriptan—Hypertension—Ezetimibe—atherosclerosis	0.000405	0.00175	CcSEcCtD
Eletriptan—Flatulence—Niacin—atherosclerosis	0.000405	0.00175	CcSEcCtD
Eletriptan—Malaise—Simvastatin—atherosclerosis	0.000404	0.00174	CcSEcCtD
Eletriptan—Tension—Niacin—atherosclerosis	0.000403	0.00174	CcSEcCtD
Eletriptan—Discomfort—Lovastatin—atherosclerosis	0.000403	0.00174	CcSEcCtD
Eletriptan—Vertigo—Simvastatin—atherosclerosis	0.000402	0.00174	CcSEcCtD
Eletriptan—Leukopenia—Simvastatin—atherosclerosis	0.000401	0.00173	CcSEcCtD
Eletriptan—Myalgia—Ezetimibe—atherosclerosis	0.0004	0.00172	CcSEcCtD
Eletriptan—Arthralgia—Ezetimibe—atherosclerosis	0.0004	0.00172	CcSEcCtD
Eletriptan—Nervousness—Niacin—atherosclerosis	0.000399	0.00172	CcSEcCtD
Eletriptan—Flatulence—Pravastatin—atherosclerosis	0.000399	0.00172	CcSEcCtD
Eletriptan—Dry mouth—Lovastatin—atherosclerosis	0.000399	0.00172	CcSEcCtD
Eletriptan—Tension—Pravastatin—atherosclerosis	0.000397	0.00171	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000397	0.00171	CcSEcCtD
Eletriptan—Dysgeusia—Pravastatin—atherosclerosis	0.000396	0.00171	CcSEcCtD
Eletriptan—Muscle spasms—Niacin—atherosclerosis	0.000395	0.0017	CcSEcCtD
Eletriptan—Discomfort—Ezetimibe—atherosclerosis	0.000395	0.0017	CcSEcCtD
Eletriptan—Constipation—Rosuvastatin—atherosclerosis	0.000394	0.0017	CcSEcCtD
Eletriptan—Pain—Rosuvastatin—atherosclerosis	0.000394	0.0017	CcSEcCtD
Eletriptan—Confusional state—Lovastatin—atherosclerosis	0.000394	0.0017	CcSEcCtD
Eletriptan—Nervousness—Pravastatin—atherosclerosis	0.000393	0.0017	CcSEcCtD
Eletriptan—Dry mouth—Ezetimibe—atherosclerosis	0.000391	0.00169	CcSEcCtD
Eletriptan—Muscle spasms—Pravastatin—atherosclerosis	0.000389	0.00168	CcSEcCtD
Eletriptan—Confusional state—Ezetimibe—atherosclerosis	0.000386	0.00167	CcSEcCtD
Eletriptan—Arthralgia—Simvastatin—atherosclerosis	0.000381	0.00164	CcSEcCtD
Eletriptan—Myalgia—Simvastatin—atherosclerosis	0.000381	0.00164	CcSEcCtD
Eletriptan—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00038	0.00164	CcSEcCtD
Eletriptan—Anxiety—Simvastatin—atherosclerosis	0.00038	0.00164	CcSEcCtD
Eletriptan—HTR7—liver—atherosclerosis	0.00038	0.0119	CbGeAlD
Eletriptan—Tremor—Pravastatin—atherosclerosis	0.000379	0.00164	CcSEcCtD
Eletriptan—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000377	0.00163	CcSEcCtD
Eletriptan—Discomfort—Simvastatin—atherosclerosis	0.000377	0.00162	CcSEcCtD
Eletriptan—Nervous system disorder—Ezetimibe—atherosclerosis	0.000376	0.00162	CcSEcCtD
Eletriptan—Angioedema—Niacin—atherosclerosis	0.000376	0.00162	CcSEcCtD
Eletriptan—Ill-defined disorder—Pravastatin—atherosclerosis	0.000376	0.00162	CcSEcCtD
Eletriptan—PTGS1—adipose tissue—atherosclerosis	0.000374	0.0118	CbGeAlD
Eletriptan—Anaemia—Pravastatin—atherosclerosis	0.000374	0.00161	CcSEcCtD
Eletriptan—Anorexia—Lovastatin—atherosclerosis	0.000372	0.00161	CcSEcCtD
Eletriptan—Skin disorder—Ezetimibe—atherosclerosis	0.000372	0.00161	CcSEcCtD
Eletriptan—CYP2C19—liver—atherosclerosis	0.000371	0.0117	CbGeAlD
Eletriptan—Angioedema—Pravastatin—atherosclerosis	0.00037	0.0016	CcSEcCtD
Eletriptan—Vertigo—Niacin—atherosclerosis	0.000369	0.00159	CcSEcCtD
Eletriptan—Syncope—Niacin—atherosclerosis	0.000369	0.00159	CcSEcCtD
Eletriptan—Confusional state—Simvastatin—atherosclerosis	0.000368	0.00159	CcSEcCtD
Eletriptan—Leukopenia—Niacin—atherosclerosis	0.000368	0.00159	CcSEcCtD
Eletriptan—Urticaria—Rosuvastatin—atherosclerosis	0.000366	0.00158	CcSEcCtD
Eletriptan—Oedema—Simvastatin—atherosclerosis	0.000365	0.00158	CcSEcCtD
Eletriptan—Malaise—Pravastatin—atherosclerosis	0.000365	0.00157	CcSEcCtD
Eletriptan—Abdominal pain—Rosuvastatin—atherosclerosis	0.000364	0.00157	CcSEcCtD
Eletriptan—Vertigo—Pravastatin—atherosclerosis	0.000364	0.00157	CcSEcCtD
Eletriptan—Palpitations—Niacin—atherosclerosis	0.000363	0.00157	CcSEcCtD
Eletriptan—Leukopenia—Pravastatin—atherosclerosis	0.000362	0.00156	CcSEcCtD
Eletriptan—Loss of consciousness—Niacin—atherosclerosis	0.000361	0.00156	CcSEcCtD
Eletriptan—Cough—Niacin—atherosclerosis	0.000359	0.00155	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000356	0.00154	CcSEcCtD
Eletriptan—Insomnia—Lovastatin—atherosclerosis	0.000353	0.00152	CcSEcCtD
Eletriptan—Cough—Pravastatin—atherosclerosis	0.000353	0.00152	CcSEcCtD
Eletriptan—Paraesthesia—Lovastatin—atherosclerosis	0.000351	0.00151	CcSEcCtD
Eletriptan—Arthralgia—Niacin—atherosclerosis	0.00035	0.00151	CcSEcCtD
Eletriptan—Myalgia—Niacin—atherosclerosis	0.00035	0.00151	CcSEcCtD
Eletriptan—Hypertension—Pravastatin—atherosclerosis	0.000349	0.00151	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000349	0.00151	CcSEcCtD
Eletriptan—Anorexia—Simvastatin—atherosclerosis	0.000348	0.0015	CcSEcCtD
Eletriptan—Dyspnoea—Lovastatin—atherosclerosis	0.000348	0.0015	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000348	0.0015	CcSEcCtD
Eletriptan—Insomnia—Ezetimibe—atherosclerosis	0.000347	0.00149	CcSEcCtD
Eletriptan—Myalgia—Pravastatin—atherosclerosis	0.000345	0.00149	CcSEcCtD
Eletriptan—Arthralgia—Pravastatin—atherosclerosis	0.000345	0.00149	CcSEcCtD
Eletriptan—Paraesthesia—Ezetimibe—atherosclerosis	0.000344	0.00148	CcSEcCtD
Eletriptan—Dyspepsia—Lovastatin—atherosclerosis	0.000344	0.00148	CcSEcCtD
Eletriptan—Anxiety—Pravastatin—atherosclerosis	0.000343	0.00148	CcSEcCtD
Eletriptan—Dry mouth—Niacin—atherosclerosis	0.000342	0.00148	CcSEcCtD
Eletriptan—Dyspnoea—Ezetimibe—atherosclerosis	0.000342	0.00147	CcSEcCtD
Eletriptan—Discomfort—Pravastatin—atherosclerosis	0.00034	0.00147	CcSEcCtD
Eletriptan—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00034	0.00146	CcSEcCtD
Eletriptan—Decreased appetite—Lovastatin—atherosclerosis	0.00034	0.00146	CcSEcCtD
Eletriptan—Dyspepsia—Ezetimibe—atherosclerosis	0.000337	0.00145	CcSEcCtD
Eletriptan—Fatigue—Lovastatin—atherosclerosis	0.000337	0.00145	CcSEcCtD
Eletriptan—Oedema—Niacin—atherosclerosis	0.000335	0.00145	CcSEcCtD
Eletriptan—Constipation—Lovastatin—atherosclerosis	0.000334	0.00144	CcSEcCtD
Eletriptan—Pain—Lovastatin—atherosclerosis	0.000334	0.00144	CcSEcCtD
Eletriptan—Confusional state—Pravastatin—atherosclerosis	0.000333	0.00144	CcSEcCtD
Eletriptan—Decreased appetite—Ezetimibe—atherosclerosis	0.000333	0.00144	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000333	0.00144	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000331	0.00143	CcSEcCtD
Eletriptan—Asthenia—Rosuvastatin—atherosclerosis	0.000331	0.00143	CcSEcCtD
Eletriptan—Insomnia—Simvastatin—atherosclerosis	0.00033	0.00143	CcSEcCtD
Eletriptan—Oedema—Pravastatin—atherosclerosis	0.00033	0.00142	CcSEcCtD
Eletriptan—Fatigue—Ezetimibe—atherosclerosis	0.00033	0.00142	CcSEcCtD
Eletriptan—Shock—Niacin—atherosclerosis	0.00033	0.00142	CcSEcCtD
Eletriptan—Paraesthesia—Simvastatin—atherosclerosis	0.000328	0.00142	CcSEcCtD
Eletriptan—Pain—Ezetimibe—atherosclerosis	0.000328	0.00141	CcSEcCtD
Eletriptan—Constipation—Ezetimibe—atherosclerosis	0.000328	0.00141	CcSEcCtD
Eletriptan—Tachycardia—Niacin—atherosclerosis	0.000327	0.00141	CcSEcCtD
Eletriptan—Pruritus—Rosuvastatin—atherosclerosis	0.000326	0.00141	CcSEcCtD
Eletriptan—Skin disorder—Niacin—atherosclerosis	0.000326	0.00141	CcSEcCtD
Eletriptan—Dyspnoea—Simvastatin—atherosclerosis	0.000326	0.00141	CcSEcCtD
Eletriptan—Hyperhidrosis—Niacin—atherosclerosis	0.000324	0.0014	CcSEcCtD
Eletriptan—Feeling abnormal—Lovastatin—atherosclerosis	0.000322	0.00139	CcSEcCtD
Eletriptan—Dyspepsia—Simvastatin—atherosclerosis	0.000322	0.00139	CcSEcCtD
Eletriptan—Anorexia—Niacin—atherosclerosis	0.00032	0.00138	CcSEcCtD
Eletriptan—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000319	0.00138	CcSEcCtD
Eletriptan—Hyperhidrosis—Pravastatin—atherosclerosis	0.000319	0.00138	CcSEcCtD
Eletriptan—Decreased appetite—Simvastatin—atherosclerosis	0.000318	0.00137	CcSEcCtD
Eletriptan—Feeling abnormal—Ezetimibe—atherosclerosis	0.000316	0.00136	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000315	0.00136	CcSEcCtD
Eletriptan—Diarrhoea—Rosuvastatin—atherosclerosis	0.000315	0.00136	CcSEcCtD
Eletriptan—Fatigue—Simvastatin—atherosclerosis	0.000315	0.00136	CcSEcCtD
Eletriptan—Anorexia—Pravastatin—atherosclerosis	0.000315	0.00136	CcSEcCtD
Eletriptan—Hypotension—Niacin—atherosclerosis	0.000313	0.00135	CcSEcCtD
Eletriptan—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000313	0.00135	CcSEcCtD
Eletriptan—Pain—Simvastatin—atherosclerosis	0.000312	0.00135	CcSEcCtD
Eletriptan—Constipation—Simvastatin—atherosclerosis	0.000312	0.00135	CcSEcCtD
Eletriptan—Urticaria—Lovastatin—atherosclerosis	0.00031	0.00134	CcSEcCtD
Eletriptan—Body temperature increased—Lovastatin—atherosclerosis	0.000309	0.00133	CcSEcCtD
Eletriptan—Abdominal pain—Lovastatin—atherosclerosis	0.000309	0.00133	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000306	0.00132	CcSEcCtD
Eletriptan—Dizziness—Rosuvastatin—atherosclerosis	0.000305	0.00131	CcSEcCtD
Eletriptan—Urticaria—Ezetimibe—atherosclerosis	0.000304	0.00131	CcSEcCtD
Eletriptan—Insomnia—Niacin—atherosclerosis	0.000303	0.00131	CcSEcCtD
Eletriptan—Body temperature increased—Ezetimibe—atherosclerosis	0.000303	0.00131	CcSEcCtD
Eletriptan—Abdominal pain—Ezetimibe—atherosclerosis	0.000303	0.00131	CcSEcCtD
Eletriptan—Paraesthesia—Niacin—atherosclerosis	0.000301	0.0013	CcSEcCtD
Eletriptan—Feeling abnormal—Simvastatin—atherosclerosis	0.000301	0.0013	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000301	0.0013	CcSEcCtD
Eletriptan—Dyspnoea—Niacin—atherosclerosis	0.000299	0.00129	CcSEcCtD
Eletriptan—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000299	0.00129	CcSEcCtD
Eletriptan—Insomnia—Pravastatin—atherosclerosis	0.000299	0.00129	CcSEcCtD
Eletriptan—Somnolence—Niacin—atherosclerosis	0.000298	0.00129	CcSEcCtD
Eletriptan—Paraesthesia—Pravastatin—atherosclerosis	0.000297	0.00128	CcSEcCtD
Eletriptan—Dyspepsia—Niacin—atherosclerosis	0.000295	0.00127	CcSEcCtD
Eletriptan—Dyspnoea—Pravastatin—atherosclerosis	0.000295	0.00127	CcSEcCtD
Eletriptan—Decreased appetite—Niacin—atherosclerosis	0.000292	0.00126	CcSEcCtD
Eletriptan—Dyspepsia—Pravastatin—atherosclerosis	0.000291	0.00125	CcSEcCtD
Eletriptan—Rash—Rosuvastatin—atherosclerosis	0.000291	0.00125	CcSEcCtD
Eletriptan—Dermatitis—Rosuvastatin—atherosclerosis	0.00029	0.00125	CcSEcCtD
Eletriptan—Urticaria—Simvastatin—atherosclerosis	0.00029	0.00125	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Niacin—atherosclerosis	0.00029	0.00125	CcSEcCtD
Eletriptan—Body temperature increased—Simvastatin—atherosclerosis	0.000289	0.00125	CcSEcCtD
Eletriptan—Abdominal pain—Simvastatin—atherosclerosis	0.000289	0.00125	CcSEcCtD
Eletriptan—Headache—Rosuvastatin—atherosclerosis	0.000289	0.00125	CcSEcCtD
Eletriptan—Hypersensitivity—Lovastatin—atherosclerosis	0.000288	0.00124	CcSEcCtD
Eletriptan—CYP2C9—liver—atherosclerosis	0.000287	0.00905	CbGeAlD
Eletriptan—Decreased appetite—Pravastatin—atherosclerosis	0.000287	0.00124	CcSEcCtD
Eletriptan—Pain—Niacin—atherosclerosis	0.000287	0.00124	CcSEcCtD
Eletriptan—Fatigue—Pravastatin—atherosclerosis	0.000285	0.00123	CcSEcCtD
Eletriptan—Constipation—Pravastatin—atherosclerosis	0.000282	0.00122	CcSEcCtD
Eletriptan—Pain—Pravastatin—atherosclerosis	0.000282	0.00122	CcSEcCtD
Eletriptan—Hypersensitivity—Ezetimibe—atherosclerosis	0.000282	0.00122	CcSEcCtD
Eletriptan—Asthenia—Lovastatin—atherosclerosis	0.00028	0.00121	CcSEcCtD
Eletriptan—Pruritus—Lovastatin—atherosclerosis	0.000276	0.00119	CcSEcCtD
Eletriptan—Asthenia—Ezetimibe—atherosclerosis	0.000275	0.00119	CcSEcCtD
Eletriptan—Gastrointestinal pain—Niacin—atherosclerosis	0.000274	0.00118	CcSEcCtD
Eletriptan—Nausea—Rosuvastatin—atherosclerosis	0.000274	0.00118	CcSEcCtD
Eletriptan—Feeling abnormal—Pravastatin—atherosclerosis	0.000272	0.00117	CcSEcCtD
Eletriptan—Pruritus—Ezetimibe—atherosclerosis	0.000271	0.00117	CcSEcCtD
Eletriptan—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00027	0.00117	CcSEcCtD
Eletriptan—Hypersensitivity—Simvastatin—atherosclerosis	0.000269	0.00116	CcSEcCtD
Eletriptan—Diarrhoea—Lovastatin—atherosclerosis	0.000267	0.00115	CcSEcCtD
Eletriptan—Urticaria—Niacin—atherosclerosis	0.000267	0.00115	CcSEcCtD
Eletriptan—Abdominal pain—Niacin—atherosclerosis	0.000265	0.00114	CcSEcCtD
Eletriptan—Body temperature increased—Niacin—atherosclerosis	0.000265	0.00114	CcSEcCtD
Eletriptan—Urticaria—Pravastatin—atherosclerosis	0.000262	0.00113	CcSEcCtD
Eletriptan—Asthenia—Simvastatin—atherosclerosis	0.000262	0.00113	CcSEcCtD
Eletriptan—Diarrhoea—Ezetimibe—atherosclerosis	0.000262	0.00113	CcSEcCtD
Eletriptan—Abdominal pain—Pravastatin—atherosclerosis	0.000261	0.00113	CcSEcCtD
Eletriptan—Body temperature increased—Pravastatin—atherosclerosis	0.000261	0.00113	CcSEcCtD
Eletriptan—Pruritus—Simvastatin—atherosclerosis	0.000259	0.00112	CcSEcCtD
Eletriptan—Dizziness—Lovastatin—atherosclerosis	0.000258	0.00111	CcSEcCtD
Eletriptan—Dizziness—Ezetimibe—atherosclerosis	0.000253	0.00109	CcSEcCtD
Eletriptan—ABCB1—cardiovascular system—atherosclerosis	0.000251	0.0079	CbGeAlD
Eletriptan—Diarrhoea—Simvastatin—atherosclerosis	0.00025	0.00108	CcSEcCtD
Eletriptan—Vomiting—Lovastatin—atherosclerosis	0.000248	0.00107	CcSEcCtD
Eletriptan—Hypersensitivity—Niacin—atherosclerosis	0.000247	0.00107	CcSEcCtD
Eletriptan—Rash—Lovastatin—atherosclerosis	0.000246	0.00106	CcSEcCtD
Eletriptan—Dermatitis—Lovastatin—atherosclerosis	0.000246	0.00106	CcSEcCtD
Eletriptan—Headache—Lovastatin—atherosclerosis	0.000245	0.00106	CcSEcCtD
Eletriptan—Vomiting—Ezetimibe—atherosclerosis	0.000244	0.00105	CcSEcCtD
Eletriptan—Hypersensitivity—Pravastatin—atherosclerosis	0.000243	0.00105	CcSEcCtD
Eletriptan—Dizziness—Simvastatin—atherosclerosis	0.000242	0.00104	CcSEcCtD
Eletriptan—Rash—Ezetimibe—atherosclerosis	0.000242	0.00104	CcSEcCtD
Eletriptan—Dermatitis—Ezetimibe—atherosclerosis	0.000241	0.00104	CcSEcCtD
Eletriptan—Asthenia—Niacin—atherosclerosis	0.000241	0.00104	CcSEcCtD
Eletriptan—Headache—Ezetimibe—atherosclerosis	0.00024	0.00104	CcSEcCtD
Eletriptan—Pruritus—Niacin—atherosclerosis	0.000237	0.00102	CcSEcCtD
Eletriptan—Asthenia—Pravastatin—atherosclerosis	0.000237	0.00102	CcSEcCtD
Eletriptan—Pruritus—Pravastatin—atherosclerosis	0.000234	0.00101	CcSEcCtD
Eletriptan—Vomiting—Simvastatin—atherosclerosis	0.000232	0.001	CcSEcCtD
Eletriptan—Nausea—Lovastatin—atherosclerosis	0.000232	0.001	CcSEcCtD
Eletriptan—Rash—Simvastatin—atherosclerosis	0.00023	0.000994	CcSEcCtD
Eletriptan—Dermatitis—Simvastatin—atherosclerosis	0.00023	0.000993	CcSEcCtD
Eletriptan—Diarrhoea—Niacin—atherosclerosis	0.00023	0.00099	CcSEcCtD
Eletriptan—Headache—Simvastatin—atherosclerosis	0.000229	0.000987	CcSEcCtD
Eletriptan—Nausea—Ezetimibe—atherosclerosis	0.000228	0.000982	CcSEcCtD
Eletriptan—Diarrhoea—Pravastatin—atherosclerosis	0.000226	0.000975	CcSEcCtD
Eletriptan—Dizziness—Niacin—atherosclerosis	0.000222	0.000957	CcSEcCtD
Eletriptan—ABCB1—adipose tissue—atherosclerosis	0.000221	0.00696	CbGeAlD
Eletriptan—CYP3A4—liver—atherosclerosis	0.000219	0.0069	CbGeAlD
Eletriptan—Dizziness—Pravastatin—atherosclerosis	0.000218	0.000942	CcSEcCtD
Eletriptan—Nausea—Simvastatin—atherosclerosis	0.000217	0.000936	CcSEcCtD
Eletriptan—CYP2D6—liver—atherosclerosis	0.000216	0.00679	CbGeAlD
Eletriptan—Vomiting—Niacin—atherosclerosis	0.000213	0.00092	CcSEcCtD
Eletriptan—Rash—Niacin—atherosclerosis	0.000212	0.000912	CcSEcCtD
Eletriptan—Dermatitis—Niacin—atherosclerosis	0.000211	0.000912	CcSEcCtD
Eletriptan—Headache—Niacin—atherosclerosis	0.00021	0.000907	CcSEcCtD
Eletriptan—Vomiting—Pravastatin—atherosclerosis	0.00021	0.000906	CcSEcCtD
Eletriptan—Rash—Pravastatin—atherosclerosis	0.000208	0.000898	CcSEcCtD
Eletriptan—Dermatitis—Pravastatin—atherosclerosis	0.000208	0.000898	CcSEcCtD
Eletriptan—Headache—Pravastatin—atherosclerosis	0.000207	0.000893	CcSEcCtD
Eletriptan—Nausea—Niacin—atherosclerosis	0.000199	0.00086	CcSEcCtD
Eletriptan—Nausea—Pravastatin—atherosclerosis	0.000196	0.000846	CcSEcCtD
Eletriptan—ABCB1—liver—atherosclerosis	0.000155	0.00488	CbGeAlD
Eletriptan—HTR2B—Signaling Pathways—PIK3CG—atherosclerosis	1.05e-05	8.14e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—HMGCR—atherosclerosis	1.05e-05	8.11e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IGF1—atherosclerosis	1.05e-05	8.11e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—SCARB1—atherosclerosis	1.05e-05	8.09e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCL2—atherosclerosis	1.04e-05	8.07e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—SCARB1—atherosclerosis	1.04e-05	8.02e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—APOE—atherosclerosis	1.03e-05	7.99e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP27A1—atherosclerosis	1.03e-05	7.97e-05	CbGpPWpGaD
Eletriptan—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	1.03e-05	7.95e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IGF1—atherosclerosis	1.03e-05	7.94e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—CAV1—atherosclerosis	1.02e-05	7.92e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—APOA1—atherosclerosis	1.02e-05	7.9e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—MAPK3—atherosclerosis	1.01e-05	7.83e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.01e-05	7.81e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—VEGFA—atherosclerosis	1.01e-05	7.81e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—MAPK3—atherosclerosis	1.01e-05	7.8e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—SERPINE1—atherosclerosis	1e-05	7.75e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—STAT3—atherosclerosis	9.99e-06	7.73e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—INS—atherosclerosis	9.96e-06	7.71e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—SERPINE1—atherosclerosis	9.94e-06	7.7e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PDGFB—atherosclerosis	9.88e-06	7.65e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—HMGCR—atherosclerosis	9.88e-06	7.64e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CG—atherosclerosis	9.85e-06	7.63e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—TGFB1—atherosclerosis	9.82e-06	7.6e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCL2—atherosclerosis	9.8e-06	7.58e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—HMGCR—atherosclerosis	9.79e-06	7.58e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	9.76e-06	7.56e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ALOX15—atherosclerosis	9.76e-06	7.56e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	9.76e-06	7.56e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—APOA2—atherosclerosis	9.76e-06	7.56e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—SERPINE1—atherosclerosis	9.74e-06	7.54e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	9.68e-06	7.5e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—AGT—atherosclerosis	9.65e-06	7.47e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ABCG5—atherosclerosis	9.64e-06	7.47e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IGF1—atherosclerosis	9.63e-06	7.46e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ABCA1—atherosclerosis	9.57e-06	7.41e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—NOS3—atherosclerosis	9.56e-06	7.4e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—MAPK3—atherosclerosis	9.54e-06	7.39e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PPARG—atherosclerosis	9.51e-06	7.36e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—NOS3—atherosclerosis	9.49e-06	7.35e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—LEP—atherosclerosis	9.45e-06	7.32e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—APOE—atherosclerosis	9.45e-06	7.32e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CAV1—atherosclerosis	9.37e-06	7.25e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—APOA1—atherosclerosis	9.34e-06	7.23e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ABCA1—atherosclerosis	9.34e-06	7.23e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—INS—atherosclerosis	9.33e-06	7.22e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CG—atherosclerosis	9.32e-06	7.21e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—LPA—atherosclerosis	9.32e-06	7.21e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—NOS3—atherosclerosis	9.3e-06	7.2e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—TGFB1—atherosclerosis	9.26e-06	7.17e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—SERPINE1—atherosclerosis	9.15e-06	7.08e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—ESR1—atherosclerosis	9.02e-06	6.99e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—BGN—atherosclerosis	9.02e-06	6.98e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PPARG—atherosclerosis	8.99e-06	6.96e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—APOA5—atherosclerosis	8.93e-06	6.91e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—F2—atherosclerosis	8.91e-06	6.9e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	8.83e-06	6.84e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—INS—atherosclerosis	8.82e-06	6.83e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ABCA1—atherosclerosis	8.8e-06	6.81e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—NOS3—atherosclerosis	8.73e-06	6.76e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ABCA1—atherosclerosis	8.73e-06	6.75e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	8.6e-06	6.65e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—ALB—atherosclerosis	8.55e-06	6.62e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CG—atherosclerosis	8.53e-06	6.6e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CXCL8—atherosclerosis	8.48e-06	6.56e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CXCL8—atherosclerosis	8.42e-06	6.52e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ALOX5—atherosclerosis	8.3e-06	6.43e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CXCL8—atherosclerosis	8.25e-06	6.38e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—HMOX1—atherosclerosis	8.21e-06	6.36e-05	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—AKT1—atherosclerosis	8.19e-06	6.34e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—NOS3—atherosclerosis	8.18e-06	6.33e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	8.17e-06	6.32e-05	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—AKT1—atherosclerosis	8.14e-06	6.3e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—ALB—atherosclerosis	8.09e-06	6.26e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—INS—atherosclerosis	8.08e-06	6.25e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—IL6—atherosclerosis	8.06e-06	6.24e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—HMOX1—atherosclerosis	8.01e-06	6.2e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—IL6—atherosclerosis	8.01e-06	6.2e-05	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—AKT1—atherosclerosis	7.97e-06	6.17e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCL2—atherosclerosis	7.95e-06	6.15e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—APOB—atherosclerosis	7.86e-06	6.09e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—IL6—atherosclerosis	7.84e-06	6.07e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IGF1—atherosclerosis	7.81e-06	6.05e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CXCL8—atherosclerosis	7.75e-06	6e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—NOS3—atherosclerosis	7.73e-06	5.99e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—APOB—atherosclerosis	7.68e-06	5.94e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MMP9—atherosclerosis	7.67e-06	5.93e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GSTM1—atherosclerosis	7.65e-06	5.92e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MMP9—atherosclerosis	7.62e-06	5.9e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—NFKB1—atherosclerosis	7.59e-06	5.87e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—HMOX1—atherosclerosis	7.55e-06	5.85e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—NFKB1—atherosclerosis	7.54e-06	5.83e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—LPL—atherosclerosis	7.51e-06	5.81e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—HMOX1—atherosclerosis	7.49e-06	5.8e-05	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—AKT1—atherosclerosis	7.48e-06	5.79e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTGS2—atherosclerosis	7.48e-06	5.79e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GSTM1—atherosclerosis	7.47e-06	5.78e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MMP9—atherosclerosis	7.46e-06	5.77e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MAPK8—atherosclerosis	7.46e-06	5.77e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NAMPT—atherosclerosis	7.45e-06	5.76e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—AKT1—atherosclerosis	7.44e-06	5.76e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	7.42e-06	5.74e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MAPK8—atherosclerosis	7.41e-06	5.73e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—LIPC—atherosclerosis	7.4e-06	5.73e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—IL6—atherosclerosis	7.4e-06	5.73e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—AKT1—atherosclerosis	7.39e-06	5.72e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	7.38e-06	5.71e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—IL6—atherosclerosis	7.37e-06	5.7e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—APOC3—atherosclerosis	7.35e-06	5.69e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—LPL—atherosclerosis	7.33e-06	5.67e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GPX1—atherosclerosis	7.33e-06	5.67e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—LDLR—atherosclerosis	7.31e-06	5.66e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	7.25e-06	5.61e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	7.23e-06	5.6e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—APOB—atherosclerosis	7.23e-06	5.6e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—APOB—atherosclerosis	7.17e-06	5.55e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GPX1—atherosclerosis	7.15e-06	5.54e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CETP—atherosclerosis	7.14e-06	5.53e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CD36—atherosclerosis	7.14e-06	5.52e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NOS3—atherosclerosis	7.08e-06	5.48e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTGS2—atherosclerosis	7.07e-06	5.48e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GSTM1—atherosclerosis	7.04e-06	5.45e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MMP9—atherosclerosis	7.01e-06	5.42e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—IL6—atherosclerosis	6.98e-06	5.4e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GSTM1—atherosclerosis	6.98e-06	5.4e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CD36—atherosclerosis	6.96e-06	5.39e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	6.93e-06	5.37e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—LPL—atherosclerosis	6.91e-06	5.35e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—VEGFA—atherosclerosis	6.88e-06	5.33e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—LPL—atherosclerosis	6.85e-06	5.3e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	6.84e-06	5.29e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—SCARB1—atherosclerosis	6.84e-06	5.29e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—AKT1—atherosclerosis	6.82e-06	5.28e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—STAT3—atherosclerosis	6.82e-06	5.28e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	6.81e-06	5.27e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	6.8e-06	5.26e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—STAT3—atherosclerosis	6.77e-06	5.24e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—MTHFR—atherosclerosis	6.76e-06	5.23e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GPX1—atherosclerosis	6.74e-06	5.22e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	6.7e-06	5.18e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GPX1—atherosclerosis	6.68e-06	5.17e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PPARA—atherosclerosis	6.63e-06	5.13e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—STAT3—atherosclerosis	6.63e-06	5.13e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—MTHFR—atherosclerosis	6.6e-06	5.11e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CD36—atherosclerosis	6.56e-06	5.08e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MAPK3—atherosclerosis	6.51e-06	5.04e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CD36—atherosclerosis	6.51e-06	5.04e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PPARA—atherosclerosis	6.47e-06	5.01e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	6.47e-06	5.01e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—HMGCR—atherosclerosis	6.46e-06	5e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—AKT1—atherosclerosis	6.44e-06	4.98e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—AGT—atherosclerosis	6.42e-06	4.97e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	6.34e-06	4.9e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TGFB1—atherosclerosis	6.32e-06	4.89e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—APOE—atherosclerosis	6.29e-06	4.87e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	6.29e-06	4.87e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	6.28e-06	4.86e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	6.28e-06	4.86e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—AGT—atherosclerosis	6.27e-06	4.85e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CAV1—atherosclerosis	6.24e-06	4.83e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—STAT3—atherosclerosis	6.23e-06	4.82e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—APOA1—atherosclerosis	6.22e-06	4.82e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—MTHFR—atherosclerosis	6.22e-06	4.81e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—MTHFR—atherosclerosis	6.17e-06	4.77e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	6.15e-06	4.76e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—APOE—atherosclerosis	6.14e-06	4.76e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PPARA—atherosclerosis	6.1e-06	4.72e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CAV1—atherosclerosis	6.09e-06	4.71e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—APOA1—atherosclerosis	6.07e-06	4.7e-05	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	6.07e-06	4.7e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PPARA—atherosclerosis	6.05e-06	4.68e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—IL6—atherosclerosis	5.97e-06	4.62e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	5.95e-06	4.61e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—AGT—atherosclerosis	5.91e-06	4.57e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—AGT—atherosclerosis	5.86e-06	4.53e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—APOE—atherosclerosis	5.79e-06	4.48e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	5.77e-06	4.47e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ABCA1—atherosclerosis	5.75e-06	4.45e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—APOE—atherosclerosis	5.74e-06	4.44e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CAV1—atherosclerosis	5.74e-06	4.44e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—APOA1—atherosclerosis	5.72e-06	4.43e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CAV1—atherosclerosis	5.69e-06	4.4e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MMP9—atherosclerosis	5.68e-06	4.4e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CG—atherosclerosis	5.68e-06	4.4e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—APOA1—atherosclerosis	5.67e-06	4.39e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	5.62e-06	4.35e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CG—atherosclerosis	5.54e-06	4.29e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	5.53e-06	4.28e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	5.51e-06	4.27e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PPARG—atherosclerosis	5.48e-06	4.24e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—INS—atherosclerosis	5.38e-06	4.16e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PPARG—atherosclerosis	5.35e-06	4.14e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—INS—atherosclerosis	5.25e-06	4.06e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CG—atherosclerosis	5.23e-06	4.04e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CG—atherosclerosis	5.18e-06	4.01e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	5.1e-06	3.95e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—STAT3—atherosclerosis	5.05e-06	3.91e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PPARG—atherosclerosis	5.04e-06	3.9e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PPARG—atherosclerosis	5e-06	3.87e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—INS—atherosclerosis	4.95e-06	3.83e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.94e-06	3.82e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ALB—atherosclerosis	4.93e-06	3.82e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—INS—atherosclerosis	4.9e-06	3.8e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	4.83e-06	3.74e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ALB—atherosclerosis	4.81e-06	3.72e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IL6—atherosclerosis	4.76e-06	3.69e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL6—atherosclerosis	4.73e-06	3.66e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—APOB—atherosclerosis	4.73e-06	3.66e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—NOS3—atherosclerosis	4.72e-06	3.65e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	4.68e-06	3.62e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL6—atherosclerosis	4.63e-06	3.59e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—NOS3—atherosclerosis	4.6e-06	3.56e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTM1—atherosclerosis	4.6e-06	3.56e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ALB—atherosclerosis	4.53e-06	3.51e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—LPL—atherosclerosis	4.52e-06	3.5e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ALB—atherosclerosis	4.5e-06	3.48e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GPX1—atherosclerosis	4.41e-06	3.41e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—AKT1—atherosclerosis	4.39e-06	3.4e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—AKT1—atherosclerosis	4.36e-06	3.38e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL6—atherosclerosis	4.35e-06	3.37e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—NOS3—atherosclerosis	4.34e-06	3.36e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTGS2—atherosclerosis	4.31e-06	3.34e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—NOS3—atherosclerosis	4.3e-06	3.33e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CD36—atherosclerosis	4.29e-06	3.32e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—AKT1—atherosclerosis	4.27e-06	3.31e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTGS2—atherosclerosis	4.21e-06	3.26e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—MTHFR—atherosclerosis	4.07e-06	3.15e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—AKT1—atherosclerosis	4.01e-06	3.11e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PPARA—atherosclerosis	3.99e-06	3.09e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTGS2—atherosclerosis	3.97e-06	3.07e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTGS2—atherosclerosis	3.93e-06	3.04e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—AGT—atherosclerosis	3.86e-06	2.99e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—APOE—atherosclerosis	3.79e-06	2.93e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—AKT1—atherosclerosis	3.76e-06	2.91e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CAV1—atherosclerosis	3.75e-06	2.9e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—APOA1—atherosclerosis	3.74e-06	2.9e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—AKT1—atherosclerosis	3.56e-06	2.75e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL6—atherosclerosis	3.53e-06	2.73e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CG—atherosclerosis	3.42e-06	2.64e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PPARG—atherosclerosis	3.3e-06	2.55e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—AKT1—atherosclerosis	3.26e-06	2.52e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—INS—atherosclerosis	3.23e-06	2.5e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ALB—atherosclerosis	2.96e-06	2.29e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NOS3—atherosclerosis	2.84e-06	2.2e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.59e-06	2.01e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—AKT1—atherosclerosis	2.17e-06	1.68e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—AKT1—atherosclerosis	2.12e-06	1.64e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—AKT1—atherosclerosis	1.99e-06	1.54e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—AKT1—atherosclerosis	1.98e-06	1.53e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—AKT1—atherosclerosis	1.3e-06	1.01e-05	CbGpPWpGaD
